CRISPR Therapeutics AG — Net Income by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1461cf0e-2138-471f-9573-65163bc672a1/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-581.6M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-048957 |
| FY 2024 | $-366.3M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-017899 |
| FY 2023 | $-153.6M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-017571 |
| FY 2022 | $-650.2M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-003441 |
| FY 2021 | $377.7M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-001282 |
| FY 2020 | $-348.9M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-006074 |
| FY 2019 | $66.9M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-004355 |
| FY 2018 | $-165.0M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-004115 |
| FY 2017 | $-68.4M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-004920 |
| FY 2016 | $-23.2M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-003977 |
| FY 2015 | $-25.5M | 2015-01-01 – 2015-12-31 | evidence 0001564590-17-003977 |
| FY 2014 | $-7.0M | 2014-01-01 – 2014-12-31 | evidence 0001564590-17-003977 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
CRISPR Therapeutics AG — all facts · Revenue · Operating Income